The prevalence of anxiety symptoms/disorders in cancer patients: a meta-analysis
ObjectiveCancer can have negative effects on mental health. The aim of this study was to investigate the prevalence of anxiety symptoms/disorders in cancer patients’ worldwide using meta-analysis.MethodsThe study population was cancer patients who had cancer at the time of the study. The outcome stu...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1422540/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846166677004222464 |
|---|---|
| author | Sohrab Amiri |
| author_facet | Sohrab Amiri |
| author_sort | Sohrab Amiri |
| collection | DOAJ |
| description | ObjectiveCancer can have negative effects on mental health. The aim of this study was to investigate the prevalence of anxiety symptoms/disorders in cancer patients’ worldwide using meta-analysis.MethodsThe study population was cancer patients who had cancer at the time of the study. The outcome studied in this study was anxiety symptoms/disorders. PubMed and Scopus were searched based on the syntax of keywords, this search was limited to articles published in English until September 2021. For this meta-analysis, data on the prevalence of anxiety were first extracted for each of the eligible studies. The random-effects method was used for the pool of all studies. Subgroup analysis was performed based on sex, anxiety disorders, cancer site, and continents. Heterogeneity in the studies was also assessed.ResultAfter evaluating and screening the studies, eighty-four studies were included in the meta-analysis. Prevalence of anxiety symptoms/disorders in cancer patients showed that this prevalence is 23% (I2 = 99.59) in the 95% confidence interval between 22-25%. This prevalence was 20% (I2 = 96.06%) in the 95% confidence interval between 15-24% in men and this prevalence is 31% (I2 = 99.72%) in the 95% confidence interval between 28-34% in women. The highest prevalence of anxiety was in patients with ovarian, breast, and lung cancers.DiscussionIt showed a high prevalence of anxiety symptoms/disorders in cancer patients, in addition to therapeutic interventions for cancer, the necessary interventions should be made on the anxiety of these patients. Methodological limitation was the heterogeneity between the studies included in the meta-analysis. Some types of cancer sites could not be studied because the number of studies was small or the site of cancer was not identified. |
| format | Article |
| id | doaj-art-5cae9384d929419b8da3b6c6155e749e |
| institution | Kabale University |
| issn | 1664-0640 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj-art-5cae9384d929419b8da3b6c6155e749e2024-11-15T11:45:17ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402024-11-011510.3389/fpsyt.2024.14225401422540The prevalence of anxiety symptoms/disorders in cancer patients: a meta-analysisSohrab AmiriObjectiveCancer can have negative effects on mental health. The aim of this study was to investigate the prevalence of anxiety symptoms/disorders in cancer patients’ worldwide using meta-analysis.MethodsThe study population was cancer patients who had cancer at the time of the study. The outcome studied in this study was anxiety symptoms/disorders. PubMed and Scopus were searched based on the syntax of keywords, this search was limited to articles published in English until September 2021. For this meta-analysis, data on the prevalence of anxiety were first extracted for each of the eligible studies. The random-effects method was used for the pool of all studies. Subgroup analysis was performed based on sex, anxiety disorders, cancer site, and continents. Heterogeneity in the studies was also assessed.ResultAfter evaluating and screening the studies, eighty-four studies were included in the meta-analysis. Prevalence of anxiety symptoms/disorders in cancer patients showed that this prevalence is 23% (I2 = 99.59) in the 95% confidence interval between 22-25%. This prevalence was 20% (I2 = 96.06%) in the 95% confidence interval between 15-24% in men and this prevalence is 31% (I2 = 99.72%) in the 95% confidence interval between 28-34% in women. The highest prevalence of anxiety was in patients with ovarian, breast, and lung cancers.DiscussionIt showed a high prevalence of anxiety symptoms/disorders in cancer patients, in addition to therapeutic interventions for cancer, the necessary interventions should be made on the anxiety of these patients. Methodological limitation was the heterogeneity between the studies included in the meta-analysis. Some types of cancer sites could not be studied because the number of studies was small or the site of cancer was not identified.https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1422540/fullanxietycancer patientsmeta-analysissystematic reviewanxiety symptoms |
| spellingShingle | Sohrab Amiri The prevalence of anxiety symptoms/disorders in cancer patients: a meta-analysis Frontiers in Psychiatry anxiety cancer patients meta-analysis systematic review anxiety symptoms |
| title | The prevalence of anxiety symptoms/disorders in cancer patients: a meta-analysis |
| title_full | The prevalence of anxiety symptoms/disorders in cancer patients: a meta-analysis |
| title_fullStr | The prevalence of anxiety symptoms/disorders in cancer patients: a meta-analysis |
| title_full_unstemmed | The prevalence of anxiety symptoms/disorders in cancer patients: a meta-analysis |
| title_short | The prevalence of anxiety symptoms/disorders in cancer patients: a meta-analysis |
| title_sort | prevalence of anxiety symptoms disorders in cancer patients a meta analysis |
| topic | anxiety cancer patients meta-analysis systematic review anxiety symptoms |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1422540/full |
| work_keys_str_mv | AT sohrabamiri theprevalenceofanxietysymptomsdisordersincancerpatientsametaanalysis AT sohrabamiri prevalenceofanxietysymptomsdisordersincancerpatientsametaanalysis |